Eli Lilly and Company

Stelis Biopharma Private Limited

Elona Biotechnologies

David John Stokell

Ronald E Zimmerman

Michael Patrick Akers

Shane Krummen Atwell

Yiqing Feng

Songqing Na

Diana Isabel Ruiz

Donmienne Leung

Laura Anne Pelletier

Maya Rachel Karta

The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.

Human interleukin-4 receptor alpha antibodies

Novel proinsulins and glargine, aspart and Lis-Pro proinsulin analogs having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production, as well as novel and highly efficient processes for preparing the same. The novel proinsulins and proinsulin analogs may be converted into human insulin and insulin analogs, respectively, that are useful in therapeutic preparations.

Insulin production methods and proinsulin constructs

Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing the pro-insulin preparations and preparations containing them are also disclosed. The novel pro-insulin preparations may be converted into human insulin useful in therapeutic preparations. Novel peptides of the C-peptide, and N terminus, including RREAEALQVGQVELGGGPGAGSLQPLALEGSLQAR (SEQ ID NO: 32), and MHHHHHHGGR (SEQ ID NO: 2) respectively are provided, as well as the unique nucleic acid molecules encoding them.

Insulin production methods and pro-insulin constructs

Growing community of inventors

Indianapolis, IN, United States of America

David John Stokell